Close Menu

GenomeWebinars

Professor of Virology, Division of Infection and Immunity, University College London & Great Ormond Street Hospital for Children

 

Target enrichment has been shown to be more sensitive than metagenomic methods and PCR amplicon sequencing for pathogen genomes, and faster than traditional methods for analysis of hard to culture pathogens, for example viruses and some bacteria.

In this webinar, Judith Breuer of University College London & Great Ormond Street Hospital for Children will show how Agilent’s SureSelect targeted enrichment technology:

  • Allows her team to generate high quality consensus sequences and preserves the population structure of minority variant sequences compared to sequencing directly from clinical samples.  
  • Enables them to interrogate clinical samples for better understanding of the evolution of drug resistance and pathogen transmission. 
  • Offers a useful tool study the impact of drugs on pathogens and the recovery of pathogen transcriptomes as part of understanding pathogenesis.

For Research Use Only. Not for use in diagnostic procedures.

Recent GenomeWebinars

Head of Business Development, Co-Diagnostics

Chief Scientific Officer, Co-Diagnostics


LGC, Biosearch Technologies, Market Segment Manager MDx, LGC


In this webinar, Joseph Featherstone and Dr. Brent Satterfield from Co-Diagnostics (CoDx) will present insights into the development of the CoPrimer COVID-19 test. They will discuss how innovative design algorithms and a close partnership with a critical component supplier, LGC, Biosearch Technologies, enabled assay design and verification in seven days, making the COVID-19 test available for market. Brent will provide details of the CoPrimer technology and how the new algorithm enabled rapid assay design, while Joseph will share the latest developments toward clinical validation of the assay as well as discuss the CoDx Portable qPCR Lab and its impact in the field.

Dr. Geert Koene from Biosearch Technologies will share the perspective of a component supplier and will discuss details of the company's proprietary BHQ technology, experience in reacting to outbreaks, and the importance of a collaborative partnership.

Sponsored by

Professor of Surgery and Emergency Medicine
Washington University School of Medicine

Instructor in the Department of Pathology & Immunology
Washington University, St. Louis

Sepsis is a growing healthcare crisis, causing over 11 million deaths worldwide. Early recognition and timely, comprehensive therapeutic interventions improve patient outcomes and have been codified in current clinical guidelines and government reporting requirements. However, non-specific presenting symptoms that mimic other diagnoses combined with multiple clinical definitions lead to diagnostic uncertainty. Identifying the undiagnosed septic patient within the sea of undifferentiated patients simultaneously presenting to the Emergency Department is challenging and can lead to potential treatment delays with associated increases in morbidity and mortality.

This webinar is presented by Dr. Tiffany Osborn, Professor of Surgery and Emergency Medicine for the Surgical/Trauma Intensive Care Unit and Emergency Department at Washington University School of Medicine and Dr. Christopher Farnsworth, instructor in the Department of Pathology & Immunology at Washington University and medical director of Clinical Chemistry, Point of Care testing, and the Special Pathogens Laboratory at Barnes Jewish Hospital.

During the session, Dr. Osborn and Dr. Farnsworth will discuss how teamwork between the laboratory and clinical medicine can improve patient care through earlier identification and treatment of septic patients. They will discuss the challenges associated with current screening biomarkers, as well as the opportunities presented by a novel sepsis biomarker, monocyte distribution width.

After this webinar, you will be able to:

  • Explain the relationship between early sepsis treatment and improved patient mortality
  • Differentiate among Sepsis-2 and Sepsis-3 definitions and common sepsis screening criteria such as qSOFA and SIRS
  • Review published evidence supporting the effectiveness of monocyte distribution width in early sepsis detection
Sponsored by
Wed
Feb
5
1:00 pm2020
Sponsored by
LGC

Development of a Novel Multiplex Assay: A Partnership Case Study

Genome Webinar

Senior Scientist, R&D Group, Co-Diagnostics 

Head of Business Development, Co-Diagnostics

General Manager, Magna Mosquito Abatement District

This webinar provides a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.          

A pivotal part of the molecular diagnostics innovation chain that is often overlooked is the relation between critical component suppliers, test manufacturers, and end users. This webinar addresses the development and utility of an innovative multiplex application for detection of Zika, dengue and chikungunya in mosquitos, enabling communities to reduce infection rates by vector control and prevent unnecessary infections and subsequent treatments.

Dr. Jana Kent, Senior Research Scientist from Co-Diagnostics (CoDx), will introduce the company’s CoPrimer technology, which provides flexibility in multiplex assay design without cross-reactivity or non-specific amplification (i.e. primer dimers). She shares insights on the development process of the Zika, dengue and chikungunya test and highlight best practices when working with critical component suppliers and end users.

Next, Ryan Lusty, General Manager of the Magna Mosquito Abatement District in Utah, discusses the implementation of this test in his county and how it impacted healthcare outcomes. Ryan discusses the importance of same-day test results for vector control, as opposed to waiting several days for state lab results.                    

Joseph Featherstone from CoDx wraps up by addressing the importance of partnership for the success of innovation, development, and commercialization of molecular diagnostics and will present opportunities for new research and commercial applications.

Sponsored by